Replies to post #27144 on CytoSorbents Corporation (CTSO)

[eskay1954]

Why waste time with these continuing cases of the week, The device failed the all important German Endocarditis trial and the Refresh trial was never going to be completed as I constantly warned due to patient size and primary endpoint of AKI which was never going to met, and just like I said, the trial was ended permanently, so here you are at 7.5 cents presplit, I remember buying 100,000 shares in 2014 for 23 cents and sold for about $6.00 bucks post split for modest profit, I saw the writing on the wall.